Idt Australia Ltd has released a press release.
IDT Divests CMAX Clinical Trial Business to Irom Group
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from IDT Australia
- Trading halt
- Cancellation of shares
- Awarded Future Industries Manufacturing Program Grant
- Completion of private placement
- CMAX - Opening of new Clinical Trial Facility
Later from IDT Australia
- IDT: 1st generic proprietary prod shipped to US, temozolomide
- Mayne Pharma Announces U.S. Launch of IDTs Temozolomide
- Completion of Initial CMAX Transaction
- Generics Sales Update
- Appendix 3Z
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia